Hereditary Syndromes

These are the AT&T CarePlus covered procedures and services effective January 1, 2022. Prior approval is required, please contact CarePlus customer care at 1-877-261-3340.

AmpliChip^® Cytochrome P450 Genotype Assay
To characterize metabolizing efficiency of CYP2D6 and CYP2C19 catalytic enzymes.

BMT/Stem Cell Transplant
For treatment of recessive dystrophic epidermolysis bullosa.

Gene-Based Testing and Genetic Counseling
For Marfan Syndrome.

Gene Transfer Therapy
For treatment of:

• Cystic Fibrosis
• Muscular Dystrophy
• Hereditary Anemias
• Hereditary and Idiopathic Thrombocytopenias

GMI-1070
For treatment of vaso-occlusive crisis in patients with Sickle Cell Disease.

Participation in Clinical Trials for Exon Skipping Compounds
Allow production of functional proteins for Duchenne muscular dystrophy. Eteplirsen, the first drug approved to treat patients with Duchenne muscular dystrophy.

Phase I, II or III Clinical Trials
When approved or sponsored by the FDA, NIH, or recognized cooperative groups, for diagnosis and/or treatment of Muscular Dystrophy (MD).

Sparsentan
A self-administered, dual mechanism (ARB and ERB), small-molecule drug for treatment of focal segmental glomerulosclerosis (FSGS).

Tafamidis
For adult patients with stage 1TTR-FAP designed to delay neurologic impairment.

Thymus/Parathyroid Transplant
For infants with complete or partial DiGeorge Syndrome.

Verigene^® Warfarin Metabolism Nucleic Acid Test
To characterize sensitivity to warfarin (Coumadin^®).